Lexicon Pharmaceuticals Inc (LXRX) Stock Analysis
Verdict: WATCH (do not buy)
Dilution risk and cash burn limit near-term upside, but pipeline catalysts in HCM and T1D offer high-risk binary upside by 2027.
Investment score: 44/100
Analysis as of
Is Lexicon Pharmaceuticals Inc stock worth reviewing? The TradeMates thesis
The TradeMates model views Lexicon Pharmaceuticals as a speculative biotech candidate best kept on WATCH. While Q1 2026 financing bolstered total cash to $199.7M, structural operating losses and upcoming Phase 3 clinical readouts in Q1 2027 require patient risk capital rather than immediate positioning.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 45/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 55/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 70/100 (weight 10%)
- Risk-Adjusted Return: 40/100 (weight 15%)
Lexicon Pharmaceuticals Inc opportunities and risks
What speaks for LXRX
- Phase 3 SONATA-HCM Trial Completion
What speaks against LXRX
- Clinical and Regulatory Binary Failure
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| LXRX | n/a | 16.3x | n/a | 98.9% | -147.4% | -11.8% |
| ALMS | n/a | 119.0x | n/a | 88.2% | -5933.5% | -40.0% |
| ANRO | n/a | 0.0x | n/a | 0.0% | 0.0% | -7.8% |
| COLL | 15.5x | 1.0x | 3.2x | 60.0% | 5.9% | 42.6% |
| Peer median | n/a | 1.0x | n/a | 60.0% | 0.0% | -7.8% |
Frequently asked questions about Lexicon Pharmaceuticals Inc (LXRX)
Is LXRX stock a good investment?
The TradeMates model rates Lexicon Pharmaceuticals Inc as WATCH (do not buy) with an investment score of 44/100. The TradeMates model views Lexicon Pharmaceuticals as a speculative biotech candidate best kept on WATCH. While Q1 2026 financing bolstered total cash to $199.7M, structural operating losses and upcoming Phase 3 clinical readouts in Q1 2027 require patient risk capital rather than immediate positioning. This is algorithmic model output, not personal investment advice.
Is LXRX stock a buy?
The TradeMates model verdict for LXRX is WATCH (do not buy) with an investment score of 44/100. Treat this as a model signal to review, not a personal buy recommendation.